BI 1026706
Unknown / undisclosed
Evidence outlook
No registered development activity since 2019
Registered studies concluded by 2019, with no US (FDA) approval on record and no active or planned study on the registry since. No sponsor statement of discontinuation has been sourced, but the trial history should be read as archival rather than an active program.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01763333 NCT01763333 · Healthy This partially randomized, single-blind, placebo-controlled Phase 1 study gave single rising oral doses of BI 1026706 to 80 healthy male volunteers and compared tablet and solution bioavailability. Its purpose was safety, tolerability and pharmacokinetics, and its registered primary outcome is drug-related adverse events with no formal efficacy test, so there is no met or missed result. Source: CT.gov posted results. Registry: NCT01763333 | 1 | Number of Subjects With Drug Related Adverse Events (From the first dose of study medication upto 15 days after the day of last intake of study medication, upto 32 days for SRD Part and 30 days for BA Part.) 2013-09-04 | Primary outcome, percentage of subjects with drug-related adverse events across single rising doses and a relative bioavailability part (no formal efficacy test); for example 25.0% at 400 mg tablet vs 22.2% on placebo (CT.gov posted results). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.